Market Cap 3.52M
Revenue (ttm) 0.00
Net Income (ttm) -12.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 10,800
Avg Vol 21,270
Day's Range N/A - N/A
Shares Out 532,000.00
Stochastic %K 16%
Beta 0.57
Analysts Sell
Price Target $30.01

Company Profile

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enha...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 913 5608
Website: decoytx.com
Address:
2450 Holcombe Blvd, Suite X, Houston, United States
MySwingAmari
MySwingAmari Jun. 8 at 12:05 PM
$DCOY Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London https://www.prnewswire.com/news-releases/decoy-therapeutics-ceo-to-participate-in-hvivo-capital-markets-day-in-london-302793469.html
0 · Reply
MySwingAmari
MySwingAmari Jun. 3 at 12:42 PM
$DCOY https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260603:nPnbDBn10a&default-theme=true
0 · Reply
MySwingAmari
MySwingAmari Jun. 3 at 12:41 PM
$DCOY - https://www.investing.com/news/company-news/decoy-therapeutics-nominates-patricia-gauthier-to-board-93CH-4724199
0 · Reply
Fromtheotherside
Fromtheotherside Jun. 1 at 8:53 PM
$DCOY Bill Gates highlighted the drug discovery platform by Decoy Therapeutics as one of the coolest innovations. Backed by a Gates Foundation grant, Decoy uses lipopeptide molecules as a decoy therapy to inhibit a virus' fusion machinery and prevent it from infecting cells, protecting people from emerging pathogens. https://www.gatesnotes.com/grand-challenges-innovations-in-senegal
0 · Reply
Fromtheotherside
Fromtheotherside Jun. 1 at 8:49 PM
$DCOY Decoy Therapeutics (DCOY) - Today’s News: Partnership with hVIVO to Advance into Clinical Stage Good news for DCOY today (June 1, 2026). Decoy Therapeutics has signed a consultancy agreement with hVIVO (a specialist in human challenge studies) to prepare their lead Designable Multi-Antiviral (D-MAV™) candidate for Phase 1 (first-in-human) and Phase 2a studies. This collaboration will support regulatory strategy (EMA/MHRA), CMC, translational modeling, and the preparation of clinical trials in Europe and the UK. Positive momentum for this pre-clinical biotech focused on pan-viral peptide conjugates. Official Press Release: https://www.prnewswire.com/news-releases/decoy-therapeutics-partners-with-hvivo-to-advance-lead-d-mav-candidate-into-the-clinic-302786694.html
0 · Reply
Jupilerke
Jupilerke Jun. 1 at 4:49 PM
$DCOY Starting a position here. 👊🤓
0 · Reply
MySwingAmari
MySwingAmari Jun. 1 at 1:18 PM
$DCOY phase 1 trial with hVivo, that’s the news explaining such a rise!
1 · Reply
RichieGreen
RichieGreen Jun. 1 at 11:53 AM
$DCOY ir looks like they’re preparing it to get shorted
0 · Reply
RichieGreen
RichieGreen Jun. 1 at 9:52 AM
$DCOY anybody knows the pre market volume?
0 · Reply
Oddpaperz
Oddpaperz Jun. 1 at 9:16 AM
$DCOY We be booming alright
0 · Reply
Latest News on DCOY
Decoy Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 8:00 AM EDT - 4 days ago

Decoy Therapeutics Proxy statement: Proxy filing


Decoy Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 8:00 AM EDT - 4 days ago

Decoy Therapeutics Proxy statement: Proxy filing


Decoy Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 4 weeks ago

Decoy Therapeutics Quarterly report: Q1 2026


Decoy Therapeutics Transcript: Status update

Apr 9, 2026, 4:00 PM EDT - 2 months ago

Decoy Therapeutics Transcript: Status update


Decoy Therapeutics Press release: Status update

Apr 9, 2026, 4:00 PM EDT - 2 months ago

Decoy Therapeutics Press release: Status update


Decoy Therapeutics regains Nasdaq compliance

2026-04-02T13:07:30.000Z - 2 months ago

Decoy Therapeutics regains Nasdaq compliance


Decoy Therapeutics Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 2 months ago

Decoy Therapeutics Annual report: Q4 2025


Decoy Therapeutics enters collaboration with Quantori

2026-03-11T12:36:44.000Z - 3 months ago

Decoy Therapeutics enters collaboration with Quantori

GOOG GOOGL


Decoy Therapeutics Inc trading halted, news pending

2026-03-07T00:50:47.000Z - 3 months ago

Decoy Therapeutics Inc trading halted, news pending


Decoy Therapeutics announces 1-for-12 reverse stock split

2026-03-05T13:54:29.000Z - 3 months ago

Decoy Therapeutics announces 1-for-12 reverse stock split


Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Mar 5, 2026, 8:30 AM EST - 3 months ago

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split


Decoy Therapeutics initiated with a Buy at Ladenburg

2026-01-23T11:40:21.000Z - 4 months ago

Decoy Therapeutics initiated with a Buy at Ladenburg


Decoy Therapeutics Proxy statement: Proxy Filing

Jan 9, 2026, 7:00 AM EST - 5 months ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 5 months ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 6 months ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 7 months ago

Decoy Therapeutics Quarterly report: Q3 2025


Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 7 months ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger


Decoy Therapeutics Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 7 months ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 7 months ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Registration statement: Registration Filing

Oct 21, 2025, 7:00 AM EDT - 8 months ago

Decoy Therapeutics Registration statement: Registration Filing


Decoy Therapeutics Registration statement: Registration Filing

Sep 23, 2025, 8:00 AM EDT - 9 months ago

Decoy Therapeutics Registration statement: Registration Filing


Decoy Therapeutics Registration statement: Registration Filing

Aug 15, 2025, 8:00 AM EDT - 10 months ago

Decoy Therapeutics Registration statement: Registration Filing


Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 10 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split


Decoy Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Decoy Therapeutics Quarterly report: Q2 2025


Decoy Therapeutics Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Decoy Therapeutics Registration statement: Registration Filing


Decoy Therapeutics Registration statement: Registration Filing

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Decoy Therapeutics Registration statement: Registration Filing


Decoy Therapeutics Proxy statement: Proxy Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

May 27, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

May 15, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

May 15, 2025, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Quarterly report: Q1 2025

May 13, 2025, 6:00 PM EDT - 1 year ago

Decoy Therapeutics Quarterly report: Q1 2025


Decoy Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Decoy Therapeutics Earnings release: Q4 2024


Decoy Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Decoy Therapeutics Annual report: Q4 2024


Decoy Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Decoy Therapeutics Quarterly report: Q3 2024


Decoy Therapeutics Proxy statement: Proxy Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Quarterly report: Q2 2024

Sep 7, 2024, 6:00 PM EDT - 1 year ago

Decoy Therapeutics Quarterly report: Q2 2024


Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split


Decoy Therapeutics Quarterly report: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Decoy Therapeutics Quarterly report: Q1 2024


Decoy Therapeutics Earnings release: Q1 2024

May 13, 2024, 4:00 PM EDT - 2 years ago

Decoy Therapeutics Earnings release: Q1 2024


Decoy Therapeutics Proxy statement: Proxy Filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Earnings release: Q4 2023

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Earnings release: Q4 2023


Decoy Therapeutics Annual report: Q4 2023

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Annual report: Q4 2023


Decoy Therapeutics Proxy statement: Proxy Filing

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Decoy Therapeutics Quarterly report: Q3 2023


Decoy Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Decoy Therapeutics Earnings release: Q3 2023


Decoy Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 4:00 PM EDT - 3 years ago

Decoy Therapeutics Quarterly report: Q2 2023


Decoy Therapeutics Earnings release: Q2 2023

Aug 10, 2023, 4:00 PM EDT - 3 years ago

Decoy Therapeutics Earnings release: Q2 2023


Decoy Therapeutics Registration statement: Registration Filing

May 26, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Registration statement: Registration Filing


Decoy Therapeutics Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Quarterly report: Q1 2023


Decoy Therapeutics Earnings release: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Earnings release: Q1 2023


Decoy Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Decoy Therapeutics Proxy statement: Proxy Filing


Decoy Therapeutics Earnings release: Q4 2022

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Earnings release: Q4 2022


Decoy Therapeutics Annual report: Q4 2022

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Decoy Therapeutics Annual report: Q4 2022


MySwingAmari
MySwingAmari Jun. 8 at 12:05 PM
$DCOY Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London https://www.prnewswire.com/news-releases/decoy-therapeutics-ceo-to-participate-in-hvivo-capital-markets-day-in-london-302793469.html
0 · Reply
MySwingAmari
MySwingAmari Jun. 3 at 12:42 PM
$DCOY https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260603:nPnbDBn10a&default-theme=true
0 · Reply
MySwingAmari
MySwingAmari Jun. 3 at 12:41 PM
$DCOY - https://www.investing.com/news/company-news/decoy-therapeutics-nominates-patricia-gauthier-to-board-93CH-4724199
0 · Reply
Fromtheotherside
Fromtheotherside Jun. 1 at 8:53 PM
$DCOY Bill Gates highlighted the drug discovery platform by Decoy Therapeutics as one of the coolest innovations. Backed by a Gates Foundation grant, Decoy uses lipopeptide molecules as a decoy therapy to inhibit a virus' fusion machinery and prevent it from infecting cells, protecting people from emerging pathogens. https://www.gatesnotes.com/grand-challenges-innovations-in-senegal
0 · Reply
Fromtheotherside
Fromtheotherside Jun. 1 at 8:49 PM
$DCOY Decoy Therapeutics (DCOY) - Today’s News: Partnership with hVIVO to Advance into Clinical Stage Good news for DCOY today (June 1, 2026). Decoy Therapeutics has signed a consultancy agreement with hVIVO (a specialist in human challenge studies) to prepare their lead Designable Multi-Antiviral (D-MAV™) candidate for Phase 1 (first-in-human) and Phase 2a studies. This collaboration will support regulatory strategy (EMA/MHRA), CMC, translational modeling, and the preparation of clinical trials in Europe and the UK. Positive momentum for this pre-clinical biotech focused on pan-viral peptide conjugates. Official Press Release: https://www.prnewswire.com/news-releases/decoy-therapeutics-partners-with-hvivo-to-advance-lead-d-mav-candidate-into-the-clinic-302786694.html
0 · Reply
Jupilerke
Jupilerke Jun. 1 at 4:49 PM
$DCOY Starting a position here. 👊🤓
0 · Reply
MySwingAmari
MySwingAmari Jun. 1 at 1:18 PM
$DCOY phase 1 trial with hVivo, that’s the news explaining such a rise!
1 · Reply
RichieGreen
RichieGreen Jun. 1 at 11:53 AM
$DCOY ir looks like they’re preparing it to get shorted
0 · Reply
RichieGreen
RichieGreen Jun. 1 at 9:52 AM
$DCOY anybody knows the pre market volume?
0 · Reply
Oddpaperz
Oddpaperz Jun. 1 at 9:16 AM
$DCOY We be booming alright
0 · Reply
Oddpaperz
Oddpaperz Jun. 1 at 12:34 AM
$DCOY https://x.com/sirmojojon/status/2061242692701405251?s=46
0 · Reply
BUKUDATBULL
BUKUDATBULL May. 31 at 3:34 PM
Some of these stocks that u should be aware of /be looking 👀 😉 MY-MONDAY-MONSTERS 👹 $DCOY $IMRN $CDT $HTCO $YYAI THIS IS NOT INVESTMENT ADVICE! But simply some potential MONSTERS 👹 🤖🤡😈👽🧌 YALL SHOULD BE ON THE WATCH 4/don't be fooled/caught without warning ⚠️ GOODLUCK/GOOD RIDDANCE ✌️
0 · Reply
Oddpaperz
Oddpaperz May. 30 at 10:41 PM
$DCOY https://x.com/sirmojojon/status/2060853845689790838?s=46
0 · Reply
Oddpaperz
Oddpaperz May. 30 at 4:05 PM
$DCOY BOOKMARK THIS! DCOY maintains a clean and well-defined capital structure with minimal near-term overhang: • Warrants: 933K shares at an average exercise price of $26 • Options: 13.7K shares at an average exercise price of $481 • Preferred Stock Conversion: 401K shares (no fixed exercise price – subject to shareholder approval) No outstanding convertible notes. This results in a highly manageable dilution profile, with the majority of potential shares tied to significantly higher strike prices well above current levels. The structure reflects strong alignment and confidence from management and key stakeholders, while keeping the float protected from aggressive or toxic financing. A disciplined capital structure built for sustainable growth.​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
0 · Reply
Natalie777
Natalie777 May. 30 at 3:48 PM
$CDT spiked 150% on Friday & now set up to RUN again. $OLOX (aka SGBX) spiked 250% on Friday & set up to RUN again. $ELPW I alerted .77 on Friday & its ready for full reversal RUN after offering closed last week. $WGRX now 3 days uptrend consolidation since 1:50 R/S last week is ready. $DCOY (aka SLRX) is ready... ALL ZERO BORROW beaten down reversals after splits. Can go very high.
2 · Reply
Oddpaperz
Oddpaperz May. 30 at 1:31 PM
$DCOY 2 catalysts in the short term: 1. Conference in Barcelona end of June (visibility, awareness) 2. Annual shareholder meeting 14th of July. Filing soon.
0 · Reply
Oddpaperz
Oddpaperz May. 30 at 12:56 PM
$HUBC $DCOY similarities explained: https://x.com/sirmojojon/status/2060701134180729069?s=46 Yes, there are clear parallels between DCOY and HUBC in this regard. Both are micro-cap/Nasdaq penny stocks that recently carried out a reverse split to meet minimum price requirements, drastically reducing the number of outstanding shares (to ~500-600K for DCOY and ~1.28M for HUBC). This creates a very low float and theoretically increases the potential for volatility and short squeezes, though the situations differ in some details
0 · Reply
Oddpaperz
Oddpaperz May. 30 at 12:54 PM
$HUBC Reminds me $DCOY https://x.com/sirmojojon/status/2060700801903792161?s=46
0 · Reply
MySwingAmari
MySwingAmari May. 30 at 6:33 AM
$DCOY Something is going on here. Who is buying this? Float 532K shares. Total volume over 10 trading days roughly 100K shares, $600K total dollar value. Stock went from $4.50 to $9.07. Perfectly linear staircase buying every single day, no retail frenzy, no spikes, just quiet controlled accumulation on a near-empty book. Then Friday May 29 happened. Flat all day, then in the last 30 minutes a single aggressive market-on-close order pushed it from $7.80 to $8.92 close, after hours $9.07. Friday was also the deadline for stockholder proposals for the July 14 annual meeting. Whoever placed that order knew exactly what day it was. Gates Foundation final tranche due first half 2026, last 30 days of that window. BARDA relationship exists. Pentelute named SAB Chair May 26 after stock already up +50%. Proxy for July 14 not yet filed. +100% move. Too controlled for retail, too small for institutions. Anyone else watching this?
1 · Reply
Oddpaperz
Oddpaperz May. 29 at 11:35 PM
$DCOY Still early.
0 · Reply
Fromtheotherside
Fromtheotherside May. 29 at 10:58 PM
$DCOY These, as you can see here, these products are positioned in very large markets. The comps for these products, a company who came up with an antibody for flu, long-acting for immunocompromised patients, was recently bought out by Merck for $9.2 billion or $221 a share. They actually use the same clinical trial program at hVIVO that we will use for our products, which is a human challenge study.
0 · Reply
Fromtheotherside
Fromtheotherside May. 29 at 3:44 PM
$DCOY Why It Dropped So Hard Over the Past Year • Toxic reverse merger (Nov 2025) with Salarius: heavy dilution for existing shareholders (share count exploded due to financings and merger structure). • Multiple reverse splits (including 1-for-12 in March 2026) to maintain Nasdaq compliance. Current Situation: The major dilution from the merger period is now behind us, reverse splits are completed, and the company has fully transitioned to Decoy Therapeutics
1 · Reply